Navigation Links
NeurogesX to Provide Qutenza® Launch Update
Date:2/9/2011

SAN MATEO, Calif., Feb. 9, 2011 /PRNewswire/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today announced it will hold a conference call on February 14, 2011 at 4:30 p.m. ET (1:30 p.m. PT) to provide an update on the U.S. commercial launch of Qutenza® (capsaicin) 8% patch for the management of neuropathic pain associated with postherpetic neuralgia (PHN).

NeurogesX will highlight key metrics for tracking U.S. physician adoption during the three month period ended December 31, 2010, approximately one month prior to filing fourth quarter 2010 financial results.

The conference call will be hosted by Anthony DiTonno, President and Chief Executive Officer, and Stephen Ghiglieri, Executive Vice President, Chief Operating Officer and Chief Financial Officer.

To participate, please dial 1-877-407-0789 (USA) or 1-201-689-8562 (International).  To access the live web cast please visit the Investor Relations section on the corporate web site at http://www.neurogesx.com.

A replay of the conference call will be available beginning February 14, 2011 at 8:00 p.m. ET (5:00 p.m. PT) and ending on February 24, 2011 by dialing 1-877-870-5176 (USA) or 1-858-384-5517 (International) with Conference ID Number: 367175.  A replay of the webcast will also be available on the corporate website through March 14, 2011.

The call will be webcast live and archived for 90 days on the investor relations section of NeurogesX' website at www.neurogesx.com.

About NeurogesX, Inc.

NeurogesX, Inc. (Nasdaq: NGSX) is a San Francisco Bay Area-based biopharmaceutical company focused on developing and commercializing novel pain management therapies. NeurogesX was founded on the concept that use of prescription-strength capsaicin could help manage the pain associated with neuropathic pain conditions. Since its inception, NeurogesX has leveraged its passion to help people with pain to efficiently develop this concept, resulting in the commercial launch of Qutenza® (capsaicin) 8% patch in 2010. The Company continues to apply its knowledge and expertise in the development of other novel treatments for pain.

The Company's lead product, Qutenza, is a localized dermal delivery system containing prescription strength capsaicin that is currently approved in the United States and the European Union. Qutenza is now available in the United States for the management of neuropathic pain associated with postherpetic neuralgia (PHN). In Europe, Qutenza is being marketed by Astellas Pharma Europe Ltd. (Astellas), the European subsidiary of Tokyo-based Astellas Pharma Inc., for the treatment of peripheral neuropathic pain in non-diabetic adults, either alone or in combination with other medicinal products for pain.

The Company is currently preparing to submit a supplemental new drug application (sNDA) to expand the U.S. label for Qutenza for the management of pain due to HIV-associated neuropathy (HIV-AN) also known as HIV-distal sensory neuropathy (HIV-DSP).

The Company's most advanced product candidate, NGX-1998, is a topically applied liquid formulation containing a high concentration of capsaicin designed to treat pain associated with neuropathic pain conditions such as PHN. NGX-1998 has completed three Phase 1 studies and patient dosing is underway in a Phase 2 clinical trial in PHN patients.

The Company's early-stage pipeline includes pre-clinical compounds which are prodrugs of acetaminophen and various opioids. The Company has evaluated certain of these compounds in vitro and in vivo.

Safe Harbor Statement

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the Act). NeurogesX disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include but are not limited to: statements regarding the upcoming launch update conference call, including potential topics to be addressed in such call; and the potential submission to the U.S. Food and Drug Administration of a supplemental new drug application for label expansion of Qutenza.  Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to: difficulties or delays in the commercialization of Qutenza, including with respect to manufacture and supply of Qutenza; unexpected adverse side effects of Qutenza; physician or patient reluctance to use Qutenza, despite the Company's efforts and strategies to commercialize Qutenza; and difficulties or delays in the further development of Qutenza and efforts towards label expansion; and potential competitors and competitive products. For further information regarding these and other risks related to NeurogesX' business, investors should consult NeurogesX' filings with the Securities and Exchange Commission.

NeurogesX, Inc.

Stephen Ghiglieri

Chief Financial Officer

(650) 358-3310




The Ruth Group

Sara Pellegrino (investors)

(646) 536-7002

spellegrino@theruthgroup.com  


Jason Rando (media)

(646) 536-7025

jrando@theruthgroup.com  





'/>"/>
SOURCE NeurogesX, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. NeurogesX to Present at Two February Investor Conferences
2. NeurogesX Receives Qutenza®-Specific J-Code From Centers for Medicare and Medicaid Services (CMS)
3. NeurogesX Doses First Patient in Phase 2 Clinical Study of NGX-1998 Liquid Capsaicin Formulation
4. NeurogesX to Hold Conference Call to Discuss Third Quarter 2010 Results
5. NeurogesX to Present at Oppenheimer & Co Healthcare Conference
6. Although NeurogesX/Astellass Qutenza is Only Approved for Postherpetic Neuralgia, Surveyed U.S. Physicians are Likely to Prescribe It for All Neuropathic Pain Types
7. NeurogesX Appoints Seasoned Sales and Marketing Executive as New Board Director
8. NeurogesX Receives FDA Approval of Qutenza(TM) (capsaicin) 8% Patch for Treatment of Postherpetic Neuralgia (PHN)
9. NeurogesX Expands Commercial Operations Leadership Team
10. NeurogesX to Hold Conference Call to Discuss Third Quarter 2009 Financial Results
11. NeurogesX to Present at JMP Securities Healthcare Focus Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... 20, 2017   Spectrum Pharmacy Products , a ... be exhibiting at the Educational Conference, February 22-25, 2017, ... Loews Coronado Bay Resort. Spectrum will be showcasing its ... Institute . The annual Educational Conference is presented by ... of Compounding Pharmacists (IACP) and the American College of ...
(Date:2/20/2017)... -- This report analyzes the worldwide markets for Human Growth ... analytics for the US, Canada , ... Asia-Pacific , and Rest of World. ... Annual estimates and forecasts are provided for the period 2015 ... these markets. Market data and analytics are derived from primary ...
(Date:2/20/2017)... 2017  This report analyzes the worldwide markets for Peripheral Arterial ... comprehensive analytics for the US, Canada , ... Asia-Pacific , Latin America ... full report: http://www.reportlinker.com/p04707127-summary/view-report.html Annual estimates and ... a six-year historic analysis is provided for these markets. Market ...
Breaking Medicine Technology:
(Date:2/20/2017)... , ... February 20, 2017 , ... ... care providers and health plan partners, announced during the 2017 Annual HIMSS ... enhancing care coordination for diabetic patients and integrating eye care into mainstream ...
(Date:2/19/2017)... ... , ... The Citadel’s new Swain Department of Nursing , along with ... Ph.D. Joseph was engaged by the college as a consultant to help build the ... a nation-wide search, she was selected to head the department as nurse administrator, assuming ...
(Date:2/19/2017)... ... February 19, 2017 , ... ProBrand Glitch is a set of 30 glitch distortion ... users can easily reveal any logo with a glitch reveal in just a few clicks ... the style and animation of each preset. Use these presets to add a uniquely animated ...
(Date:2/19/2017)... , ... February 19, 2017 , ... ... for connected home healthcare, will join forces with Healthwise ® at ... Healthwise, the industry leader in evidence-based health education, technology and services, will ...
(Date:2/18/2017)... Waltham, Massachusetts (PRWEB) , ... February 17, 2017 ... ... be the leading source of disruptive innovation in the industry, according to the ... Insights Reports are based on surveys of the NEJM Catalyst Insights Council, a ...
Breaking Medicine News(10 mins):